The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Seasonal Affective Disorder Therapeutics Market Research Report 2025
Synopsis
Seasonal affective disorder (SAD) is a mood disorder subset in which people who have normal mental health throughout most of the year exhibit depressive symptoms at the same time each year, most commonly in the winter. Common symptoms include sleeping too much, having little to no energy, and overeating. The condition in the summer can include heightened anxiety.
The global Seasonal Affective Disorder Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Seasonal Affective Disorder Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Seasonal Affective Disorder Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Seasonal Affective Disorder Therapeutics in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Seasonal Affective Disorder Therapeutics include Allergan, Pfizer, Roche, Eli Lily, GlaxoSmithKline, Teva Pharmaceuticals, Bausch Health Companies, Mylan and Sanofi, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Seasonal Affective Disorder Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Seasonal Affective Disorder Therapeutics.
Report Scope
The Seasonal Affective Disorder Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Seasonal Affective Disorder Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Seasonal Affective Disorder Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan
Pfizer
Roche
Eli Lily
GlaxoSmithKline
Teva Pharmaceuticals
Bausch Health Companies
Mylan
Sanofi
Novartis
Johnson & Johnson
Koninklijke Philips
Beurer GmbH
Lucimed (Luminette)
Segment by Type
Light Therapy (Phototherapy)
Medication
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Seasonal Affective Disorder Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Seasonal affective disorder (SAD) is a mood disorder subset in which people who have normal mental health throughout most of the year exhibit depressive symptoms at the same time each year, most commonly in the winter. Common symptoms include sleeping too much, having little to no energy, and overeating. The condition in the summer can include heightened anxiety.
The global Seasonal Affective Disorder Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Seasonal Affective Disorder Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Seasonal Affective Disorder Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Seasonal Affective Disorder Therapeutics in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Seasonal Affective Disorder Therapeutics include Allergan, Pfizer, Roche, Eli Lily, GlaxoSmithKline, Teva Pharmaceuticals, Bausch Health Companies, Mylan and Sanofi, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Seasonal Affective Disorder Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Seasonal Affective Disorder Therapeutics.
Report Scope
The Seasonal Affective Disorder Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Seasonal Affective Disorder Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Seasonal Affective Disorder Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan
Pfizer
Roche
Eli Lily
GlaxoSmithKline
Teva Pharmaceuticals
Bausch Health Companies
Mylan
Sanofi
Novartis
Johnson & Johnson
Koninklijke Philips
Beurer GmbH
Lucimed (Luminette)
Segment by Type
Light Therapy (Phototherapy)
Medication
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Seasonal Affective Disorder Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Seasonal Affective Disorder Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Light Therapy (Phototherapy)
1.2.3 Medication
1.2.4 Others
1.3 Market by Application
1.3.1 Global Seasonal Affective Disorder Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Seasonal Affective Disorder Therapeutics Market Perspective (2019-2030)
2.2 Seasonal Affective Disorder Therapeutics Growth Trends by Region
2.2.1 Global Seasonal Affective Disorder Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Seasonal Affective Disorder Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Seasonal Affective Disorder Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Seasonal Affective Disorder Therapeutics Market Dynamics
2.3.1 Seasonal Affective Disorder Therapeutics Industry Trends
2.3.2 Seasonal Affective Disorder Therapeutics Market Drivers
2.3.3 Seasonal Affective Disorder Therapeutics Market Challenges
2.3.4 Seasonal Affective Disorder Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Seasonal Affective Disorder Therapeutics Players by Revenue
3.1.1 Global Top Seasonal Affective Disorder Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Seasonal Affective Disorder Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Seasonal Affective Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Seasonal Affective Disorder Therapeutics Revenue
3.4 Global Seasonal Affective Disorder Therapeutics Market Concentration Ratio
3.4.1 Global Seasonal Affective Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Seasonal Affective Disorder Therapeutics Revenue in 2023
3.5 Seasonal Affective Disorder Therapeutics Key Players Head office and Area Served
3.6 Key Players Seasonal Affective Disorder Therapeutics Product Solution and Service
3.7 Date of Enter into Seasonal Affective Disorder Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Seasonal Affective Disorder Therapeutics Breakdown Data by Type
4.1 Global Seasonal Affective Disorder Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Seasonal Affective Disorder Therapeutics Forecasted Market Size by Type (2025-2030)
5 Seasonal Affective Disorder Therapeutics Breakdown Data by Application
5.1 Global Seasonal Affective Disorder Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Seasonal Affective Disorder Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Seasonal Affective Disorder Therapeutics Market Size (2019-2030)
6.2 North America Seasonal Affective Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Seasonal Affective Disorder Therapeutics Market Size by Country (2019-2024)
6.4 North America Seasonal Affective Disorder Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Seasonal Affective Disorder Therapeutics Market Size (2019-2030)
7.2 Europe Seasonal Affective Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Seasonal Affective Disorder Therapeutics Market Size by Country (2019-2024)
7.4 Europe Seasonal Affective Disorder Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Seasonal Affective Disorder Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Seasonal Affective Disorder Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Seasonal Affective Disorder Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Seasonal Affective Disorder Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Seasonal Affective Disorder Therapeutics Market Size (2019-2030)
9.2 Latin America Seasonal Affective Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Seasonal Affective Disorder Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Seasonal Affective Disorder Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Seasonal Affective Disorder Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Seasonal Affective Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Seasonal Affective Disorder Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Seasonal Affective Disorder Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Allergan
11.1.1 Allergan Company Detail
11.1.2 Allergan Business Overview
11.1.3 Allergan Seasonal Affective Disorder Therapeutics Introduction
11.1.4 Allergan Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024)
11.1.5 Allergan Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Seasonal Affective Disorder Therapeutics Introduction
11.2.4 Pfizer Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche Seasonal Affective Disorder Therapeutics Introduction
11.3.4 Roche Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024)
11.3.5 Roche Recent Development
11.4 Eli Lily
11.4.1 Eli Lily Company Detail
11.4.2 Eli Lily Business Overview
11.4.3 Eli Lily Seasonal Affective Disorder Therapeutics Introduction
11.4.4 Eli Lily Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024)
11.4.5 Eli Lily Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Detail
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Seasonal Affective Disorder Therapeutics Introduction
11.5.4 GlaxoSmithKline Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024)
11.5.5 GlaxoSmithKline Recent Development
11.6 Teva Pharmaceuticals
11.6.1 Teva Pharmaceuticals Company Detail
11.6.2 Teva Pharmaceuticals Business Overview
11.6.3 Teva Pharmaceuticals Seasonal Affective Disorder Therapeutics Introduction
11.6.4 Teva Pharmaceuticals Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024)
11.6.5 Teva Pharmaceuticals Recent Development
11.7 Bausch Health Companies
11.7.1 Bausch Health Companies Company Detail
11.7.2 Bausch Health Companies Business Overview
11.7.3 Bausch Health Companies Seasonal Affective Disorder Therapeutics Introduction
11.7.4 Bausch Health Companies Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024)
11.7.5 Bausch Health Companies Recent Development
11.8 Mylan
11.8.1 Mylan Company Detail
11.8.2 Mylan Business Overview
11.8.3 Mylan Seasonal Affective Disorder Therapeutics Introduction
11.8.4 Mylan Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024)
11.8.5 Mylan Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Detail
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Seasonal Affective Disorder Therapeutics Introduction
11.9.4 Sanofi Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024)
11.9.5 Sanofi Recent Development
11.10 Novartis
11.10.1 Novartis Company Detail
11.10.2 Novartis Business Overview
11.10.3 Novartis Seasonal Affective Disorder Therapeutics Introduction
11.10.4 Novartis Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024)
11.10.5 Novartis Recent Development
11.11 Johnson & Johnson
11.11.1 Johnson & Johnson Company Detail
11.11.2 Johnson & Johnson Business Overview
11.11.3 Johnson & Johnson Seasonal Affective Disorder Therapeutics Introduction
11.11.4 Johnson & Johnson Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024)
11.11.5 Johnson & Johnson Recent Development
11.12 Koninklijke Philips
11.12.1 Koninklijke Philips Company Detail
11.12.2 Koninklijke Philips Business Overview
11.12.3 Koninklijke Philips Seasonal Affective Disorder Therapeutics Introduction
11.12.4 Koninklijke Philips Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024)
11.12.5 Koninklijke Philips Recent Development
11.13 Beurer GmbH
11.13.1 Beurer GmbH Company Detail
11.13.2 Beurer GmbH Business Overview
11.13.3 Beurer GmbH Seasonal Affective Disorder Therapeutics Introduction
11.13.4 Beurer GmbH Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024)
11.13.5 Beurer GmbH Recent Development
11.14 Lucimed (Luminette)
11.14.1 Lucimed (Luminette) Company Detail
11.14.2 Lucimed (Luminette) Business Overview
11.14.3 Lucimed (Luminette) Seasonal Affective Disorder Therapeutics Introduction
11.14.4 Lucimed (Luminette) Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024)
11.14.5 Lucimed (Luminette) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Seasonal Affective Disorder Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Light Therapy (Phototherapy)
Table 3. Key Players of Medication
Table 4. Key Players of Others
Table 5. Global Seasonal Affective Disorder Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Seasonal Affective Disorder Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Seasonal Affective Disorder Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Seasonal Affective Disorder Therapeutics Market Share by Region (2019-2024)
Table 9. Global Seasonal Affective Disorder Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Seasonal Affective Disorder Therapeutics Market Share by Region (2025-2030)
Table 11. Seasonal Affective Disorder Therapeutics Market Trends
Table 12. Seasonal Affective Disorder Therapeutics Market Drivers
Table 13. Seasonal Affective Disorder Therapeutics Market Challenges
Table 14. Seasonal Affective Disorder Therapeutics Market Restraints
Table 15. Global Seasonal Affective Disorder Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Seasonal Affective Disorder Therapeutics Market Share by Players (2019-2024)
Table 17. Global Top Seasonal Affective Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Seasonal Affective Disorder Therapeutics as of 2023)
Table 18. Ranking of Global Top Seasonal Affective Disorder Therapeutics Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Seasonal Affective Disorder Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Seasonal Affective Disorder Therapeutics Product Solution and Service
Table 22. Date of Enter into Seasonal Affective Disorder Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Seasonal Affective Disorder Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Seasonal Affective Disorder Therapeutics Revenue Market Share by Type (2019-2024)
Table 26. Global Seasonal Affective Disorder Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Seasonal Affective Disorder Therapeutics Revenue Market Share by Type (2025-2030)
Table 28. Global Seasonal Affective Disorder Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Seasonal Affective Disorder Therapeutics Revenue Market Share by Application (2019-2024)
Table 30. Global Seasonal Affective Disorder Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Seasonal Affective Disorder Therapeutics Revenue Market Share by Application (2025-2030)
Table 32. North America Seasonal Affective Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Seasonal Affective Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Seasonal Affective Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Seasonal Affective Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Seasonal Affective Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Seasonal Affective Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Seasonal Affective Disorder Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Seasonal Affective Disorder Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Seasonal Affective Disorder Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Seasonal Affective Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Seasonal Affective Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Seasonal Affective Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Seasonal Affective Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Seasonal Affective Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Seasonal Affective Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 47. Allergan Company Detail
Table 48. Allergan Business Overview
Table 49. Allergan Seasonal Affective Disorder Therapeutics Product
Table 50. Allergan Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 51. Allergan Recent Development
Table 52. Pfizer Company Detail
Table 53. Pfizer Business Overview
Table 54. Pfizer Seasonal Affective Disorder Therapeutics Product
Table 55. Pfizer Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 56. Pfizer Recent Development
Table 57. Roche Company Detail
Table 58. Roche Business Overview
Table 59. Roche Seasonal Affective Disorder Therapeutics Product
Table 60. Roche Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 61. Roche Recent Development
Table 62. Eli Lily Company Detail
Table 63. Eli Lily Business Overview
Table 64. Eli Lily Seasonal Affective Disorder Therapeutics Product
Table 65. Eli Lily Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 66. Eli Lily Recent Development
Table 67. GlaxoSmithKline Company Detail
Table 68. GlaxoSmithKline Business Overview
Table 69. GlaxoSmithKline Seasonal Affective Disorder Therapeutics Product
Table 70. GlaxoSmithKline Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 71. GlaxoSmithKline Recent Development
Table 72. Teva Pharmaceuticals Company Detail
Table 73. Teva Pharmaceuticals Business Overview
Table 74. Teva Pharmaceuticals Seasonal Affective Disorder Therapeutics Product
Table 75. Teva Pharmaceuticals Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 76. Teva Pharmaceuticals Recent Development
Table 77. Bausch Health Companies Company Detail
Table 78. Bausch Health Companies Business Overview
Table 79. Bausch Health Companies Seasonal Affective Disorder Therapeutics Product
Table 80. Bausch Health Companies Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 81. Bausch Health Companies Recent Development
Table 82. Mylan Company Detail
Table 83. Mylan Business Overview
Table 84. Mylan Seasonal Affective Disorder Therapeutics Product
Table 85. Mylan Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 86. Mylan Recent Development
Table 87. Sanofi Company Detail
Table 88. Sanofi Business Overview
Table 89. Sanofi Seasonal Affective Disorder Therapeutics Product
Table 90. Sanofi Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 91. Sanofi Recent Development
Table 92. Novartis Company Detail
Table 93. Novartis Business Overview
Table 94. Novartis Seasonal Affective Disorder Therapeutics Product
Table 95. Novartis Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 96. Novartis Recent Development
Table 97. Johnson & Johnson Company Detail
Table 98. Johnson & Johnson Business Overview
Table 99. Johnson & Johnson Seasonal Affective Disorder Therapeutics Product
Table 100. Johnson & Johnson Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 101. Johnson & Johnson Recent Development
Table 102. Koninklijke Philips Company Detail
Table 103. Koninklijke Philips Business Overview
Table 104. Koninklijke Philips Seasonal Affective Disorder Therapeutics Product
Table 105. Koninklijke Philips Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 106. Koninklijke Philips Recent Development
Table 107. Beurer GmbH Company Detail
Table 108. Beurer GmbH Business Overview
Table 109. Beurer GmbH Seasonal Affective Disorder Therapeutics Product
Table 110. Beurer GmbH Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 111. Beurer GmbH Recent Development
Table 112. Lucimed (Luminette) Company Detail
Table 113. Lucimed (Luminette) Business Overview
Table 114. Lucimed (Luminette) Seasonal Affective Disorder Therapeutics Product
Table 115. Lucimed (Luminette) Revenue in Seasonal Affective Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 116. Lucimed (Luminette) Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Seasonal Affective Disorder Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Seasonal Affective Disorder Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Light Therapy (Phototherapy) Features
Figure 4. Medication Features
Figure 5. Others Features
Figure 6. Global Seasonal Affective Disorder Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Seasonal Affective Disorder Therapeutics Market Share by Application: 2023 VS 2030
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Others Case Studies
Figure 11. Seasonal Affective Disorder Therapeutics Report Years Considered
Figure 12. Global Seasonal Affective Disorder Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Seasonal Affective Disorder Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Seasonal Affective Disorder Therapeutics Market Share by Region: 2023 VS 2030
Figure 15. Global Seasonal Affective Disorder Therapeutics Market Share by Players in 2023
Figure 16. Global Top Seasonal Affective Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Seasonal Affective Disorder Therapeutics as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Seasonal Affective Disorder Therapeutics Revenue in 2023
Figure 18. North America Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Seasonal Affective Disorder Therapeutics Market Share by Country (2019-2030)
Figure 20. United States Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Seasonal Affective Disorder Therapeutics Market Share by Country (2019-2030)
Figure 24. Germany Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Seasonal Affective Disorder Therapeutics Market Share by Region (2019-2030)
Figure 32. China Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Seasonal Affective Disorder Therapeutics Market Share by Country (2019-2030)
Figure 40. Mexico Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Seasonal Affective Disorder Therapeutics Market Share by Country (2019-2030)
Figure 44. Turkey Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Seasonal Affective Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Allergan Revenue Growth Rate in Seasonal Affective Disorder Therapeutics Business (2019-2024)
Figure 47. Pfizer Revenue Growth Rate in Seasonal Affective Disorder Therapeutics Business (2019-2024)
Figure 48. Roche Revenue Growth Rate in Seasonal Affective Disorder Therapeutics Business (2019-2024)
Figure 49. Eli Lily Revenue Growth Rate in Seasonal Affective Disorder Therapeutics Business (2019-2024)
Figure 50. GlaxoSmithKline Revenue Growth Rate in Seasonal Affective Disorder Therapeutics Business (2019-2024)
Figure 51. Teva Pharmaceuticals Revenue Growth Rate in Seasonal Affective Disorder Therapeutics Business (2019-2024)
Figure 52. Bausch Health Companies Revenue Growth Rate in Seasonal Affective Disorder Therapeutics Business (2019-2024)
Figure 53. Mylan Revenue Growth Rate in Seasonal Affective Disorder Therapeutics Business (2019-2024)
Figure 54. Sanofi Revenue Growth Rate in Seasonal Affective Disorder Therapeutics Business (2019-2024)
Figure 55. Novartis Revenue Growth Rate in Seasonal Affective Disorder Therapeutics Business (2019-2024)
Figure 56. Johnson & Johnson Revenue Growth Rate in Seasonal Affective Disorder Therapeutics Business (2019-2024)
Figure 57. Koninklijke Philips Revenue Growth Rate in Seasonal Affective Disorder Therapeutics Business (2019-2024)
Figure 58. Beurer GmbH Revenue Growth Rate in Seasonal Affective Disorder Therapeutics Business (2019-2024)
Figure 59. Lucimed (Luminette) Revenue Growth Rate in Seasonal Affective Disorder Therapeutics Business (2019-2024)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
